Long-Term Use of Bonviva® for the Treatment of Postmenopausal Osteoporosis: New Evidence

O.B. Yershova, K.Yu. Belova, A.V. Nazarova

Abstract


Osteoporosis is a disease of great social importance. Its treatment is a complicated problem and is associated with low compliance and a risk for adverse reactions. Ibandronate belongs to a group of bisphosphonates. The performed trials have proven the efficacy of its two formulations (a tablet once monthly and intravenous injection once every 3 months) in reducing the risk of bone fractures. At present there are data on trials of long-term therapy with this drug, which demonstrate its positive effect on bone mineral density and bone metabolism markers. In addition, high safety of the drug has been shown in long-term use.


Keywords


osteoporosis; bisphosphonates; ibandronate; risk of fracture

References


Клинические рекомендации по диагностике, лечению и профилактике остеопороза. — М., 2008. — 176 с.

Cramer J.A., Gold D.T., Silverman S.L. et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis // Osteopor Int. — 2007. — 18. — 1023-103.

Landfeldt E., Strom O., Robbins S. et al. Adherence to treatment of primary osteoporosis and its association to fractures — the Swedish Adherence Register Analysis (SARA) // Osteopor. Int. (in press).

Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) // Curr. Med. Res. Opin. — 2005. — 21 (12). — 1895-903.

Hadji P., Minne H., Pfeifer M. et al. Treatment preferen­ce for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II) // Joint Bone Spine. — 2007. — 75 (3). — 303-10.

Cooper A., Drake J., Brankin E. Investigators PERSIST (2006). Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study // Int. J. Clin. Pract. — 60. — 896-905.

Barrett J., Worth E., Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update // J. Clin. Pharmacol. — 2004. — 44. — 951-65.

Dando T.M., Noble S. Once-monthly ibandronate // Treat. Endocrin. — 2005. — 4 (6). — 381-7.

Croom K.F., Scott L.J. Intravenous ibandronate: in the treatment of osteoporosis // Drugs. — 2006. — 66 (12). — 1593-601.

Russell R.G., Watts N.B., Ebetino F.H. et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy // Osteopor. Int. — 2008. — 19 (6). — 732-59.

Chesnut 3rd C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis // J. Bone Miner. Res. — 2004. — 19 (8). — 1241-9.

Bachmann G., Barr C.E., Gass M. Ibandronate reduces fracture rates in patients younger than 60 years with low lumbar spine bone mineral density // Obstet. Gynecol. — 2006. — 107 (Suppl. 4). — 82-3.

Felsenberg D., Miller P., Armbrecht G. et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis // Bone. — 2005. — 37 (5). — 651-4.

Miller P.D., McClung M.R., Macovei L. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study // J. Bone Miner. Res. — 2005. — 20 (8). — 1315-22.

Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study // Ann. Rheum. Dis. — 2006. — 65 (5). — 654-61.

Miller P.D., Epstein S., Sedarati F. et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study // Curr. Med. Res. Opin. — 2008. — 24 (1). — 207-13.

Stakkestad J.A., Lakatos P., Lorenc R. et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the ­MOBILE long-term extension // Clin. Rheum. — 2008. — 27 (8). — 955-60.

Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study // Arthr. Rheum. — 2006. — 54 (6). — 1838-46.

Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study // J. Rheum. — 2008. — 35 (3). — 488-97.

Recknor C., Lillestol M., Grant R. et al. Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension [abstract no. W363] // J. Bone Miner. Res. — 2007. — 22 (Suppl. 1). — 453.

Bianchi G., Garcia-Hernandez P., Grant R. et al. The ­DIVA study long-term extension: maintained efficacy with quarterly intravenous ibandronate injection [abstr no. SAT0292] // 2007 Annual European Congress of Rheumatology. — 2007 Jun 13–16, Barcelona.

Emkey R., Chesnut 3rd C.H., Schimmer R.C. et al. Benefits of oral ibandronate on non-vertebral fracture risk in postmenopausal osteoporosis: further analyses from a pivotal phase III study [abstract no. T389] // J. Bone Miner. Res. — 2007. — 22 (Suppl. 1). — S329.

Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment // Curr. Osteopor. Rep. — 2009. — 7. — 12-7.

Bone H.G., Hosking D., Devogelaer J.-P. et al. Alendronate Phase III Osteoporosis Treatment Study Group Ten years’ experience with alendronate for osteoporosis in postmenopausal women // N. Engl. J. Med. — 2004. — 350. — 1189-99.

Mellstrom D.D., Sorensen O.H., Goemaere S. et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis // Calcif. Tissue Int. — 2004. — 75. — 462-8.

Black D., Reid I., Cauley J. et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON Pivotal Fracture Trial (PFT) // J. Bone Miner. Res. — 2010. — 25 (Suppl. 1). — 1070. Available at http:// www.asbmr.org/Meetings/AnnualMeet ing/AbstractDetail.aspx?aid=4781a020-dc3a-46be-b49d-f706b5509c4e Acces 13 Jan 2011.

Reginster J.-Y., Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates // Clin. Interv. Aging. — 2006. — 1. — 415-23.

Reginster J.Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study// Ann. Rheum. Dis. — 2006. — 65. — 654-61.

Miller P.D., Recker R.R., Reginster J.Y. et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE longterm extension study // Osteopor. Int. — 2011 [Epub ahead of print].

Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: oneyear results from the dosing intravenous administration study // Arthr. Rheum. — 2006. — 54. — 1838-46.

Bianchi G., Czerwinski E., Kenwright A. et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study longterm extension // Osteopor. Int. — 2011 [Epub ahead of print].

Garnero P., Borel O., Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis // Clin. Chem. — 2001. — 47. — 694-702.

Garnero P., Vergnaud P., Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis // Clin. Chem. — 2008. — 54. — 188-96.




DOI: https://doi.org/10.22141/2224-1507.1.9.2013.81978

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru